In a report released today, Bob Hopkins from Merrill Lynch maintained a Buy rating on Edwards Lifesciences (EW), with a price target of $215. The company’s shares closed on Friday at $179.75, close to its 52-week high of $181.43.
According to TipRanks.com, Hopkins is a 4-star analyst with an average return of 10.9% and a 72.0% success rate. Hopkins covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Avedro Inc, and Nevro.
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $179.67, a 0.0% downside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $215 price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences’ market cap is currently $37.33B and has a P/E ratio of 53.34. The company has a Price to Book ratio of 11.89.
Based on the recent corporate insider activity of 119 insiders, corporate insider sentiment is negative on the stock. Last month, Robert Sellers, the VP, Corp. Contr of EW sold 500 shares for a total of $87,515.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care.
